Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers (Q37730020)

22 August 2017

1 reference

title

Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers (English)

1 reference

22 August 2017

0 references

Liliane Goetsch

1 reference

22 August 2017

Véronique Caussanel

series ordinal

1 reference

22 August 2017

publication date

1 February 2010

1 reference

22 August 2017

published in

Biomarkers in Medicine

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

149-170

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

22 August 2017

cites work

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways.

21 January 2018

1 reference

The mutationally activated Met receptor mediates motility and metastasis

21 January 2018

1 reference

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

21 January 2018

1 reference

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

A novel germ line juxtamembrane Met mutation in human gastric cancer

21 January 2018

1 reference

Tyrosine kinase receptor indistinguishable from the c-met protein

21 January 2018

1 reference

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors

21 January 2018

1 reference

Met, metastasis, motility and more

21 January 2018

1 reference

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

21 January 2018

1 reference

Scatter factor/hepatocyte growth factor is essential for liver development

21 January 2018

1 reference

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

21 January 2018

1 reference

Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and inducti

21 January 2018

1 reference

Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros

21 January 2018

1 reference

Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland

21 January 2018

1 reference

Overexpression of the Met/HGF receptor in ovarian cancer.

21 January 2018

1 reference

Overexpression of the met/HGF receptor in renal cell carcinomas

21 January 2018

1 reference

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

21 January 2018

1 reference

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase

21 January 2018

1 reference

The Met pathway: master switch and drug target in cancer progression

21 January 2018

1 reference

Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures

21 January 2018

1 reference

A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor

21 January 2018

1 reference

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

21 January 2018

1 reference

Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells

21 January 2018

1 reference

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

21 January 2018

1 reference

Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network

21 January 2018

1 reference

Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor

21 January 2018

1 reference

Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells

21 January 2018

1 reference

The met proto-oncogene receptor and lumen formation

21 January 2018

1 reference

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

21 January 2018

1 reference

Scatter factor induces blood vessel formation in vivo

21 January 2018

1 reference

The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met

21 January 2018

1 reference

Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation

21 January 2018

1 reference

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

21 January 2018

1 reference

RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival

21 January 2018

1 reference

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

21 January 2018

1 reference

Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy

21 January 2018

1 reference

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

21 January 2018

1 reference

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

21 January 2018

1 reference

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

21 January 2018

1 reference

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

21 January 2018

1 reference

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts

21 January 2018

1 reference

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.

21 January 2018

1 reference

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

21 January 2018

1 reference

MET overexpression turns human primary osteoblasts into osteosarcomas.

21 January 2018

1 reference

Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice

21 January 2018

1 reference

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization

21 January 2018

1 reference

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

21 January 2018

1 reference

Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features.

21 January 2018

1 reference

The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors

21 January 2018

1 reference

Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection.

21 January 2018

1 reference

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer

21 January 2018

1 reference

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

21 January 2018

1 reference

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin

21 January 2018

1 reference

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

21 January 2018

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

21 January 2018

1 reference

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

21 January 2018

1 reference

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

21 January 2018

1 reference

Uncovering therapeutic targets for glioblastoma: a systems biology approach

21 January 2018

1 reference

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases

21 January 2018

1 reference

Expression of c-met is a strong independent prognostic factor in breast carcinoma

21 January 2018

1 reference

Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

21 January 2018

1 reference

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion

21 January 2018

1 reference

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

21 January 2018

1 reference

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential

21 January 2018

1 reference

Activating mutations for the met tyrosine kinase receptor in human cancer

21 January 2018

1 reference

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

21 January 2018

1 reference

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

21 January 2018

1 reference

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

21 January 2018

1 reference

Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx

21 January 2018

1 reference

C-terminal truncated forms of Met, the hepatocyte growth factor receptor

21 January 2018

1 reference

Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form.

21 January 2018

1 reference

Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met).

21 January 2018

1 reference

c-Met ectodomain shedding rate correlates with malignant potential

21 January 2018

1 reference

Genetic profile of gliosarcomas

21 January 2018

1 reference

PTEN and the PI3-kinase pathway in cancer

21 January 2018

1 reference

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy

21 January 2018

1 reference

Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis

21 January 2018

1 reference

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

21 January 2018

1 reference

The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization

21 January 2018

1 reference

Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase

21 January 2018

1 reference

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

21 January 2018

1 reference

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

21 January 2018

1 reference

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras

21 January 2018

1 reference

c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma

21 January 2018

1 reference

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

21 January 2018

1 reference

Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis

21 January 2018

1 reference

Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer

21 January 2018

1 reference

Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor

21 January 2018

1 reference

Serum levels of hepatocyte growth factor in patients with breast cancer

21 January 2018

1 reference

Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer

21 January 2018

1 reference

Molecular cancer therapy: can our expectation be MET?

21 January 2018

1 reference

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

21 January 2018

1 reference

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

21 January 2018

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation

21 January 2018

1 reference

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.09.67

1 reference

22 August 2017

1 reference